Generic Drug Pricing Policies in India: DPCO 2013 and What It Means for Export Buyers

India's pharmaceutical pricing policy has a direct — if sometimes counterintuitive — effect on the prices international buyers pay for Indian medicines. Understanding the Drug Price Control Order (DPCO) 2013 and the National Pharmaceutical Pricing Authority (NPPA) helps buyers interpret Indian pharmaceutical pricing with greater clarity.

---

What Is the DPCO?

The Drug Price Control Order (DPCO) is issued by the Government of India under the Essential Commodities Act. The DPCO empowers the National Pharmaceutical Pricing Authority (NPPA) to fix and regulate the prices of specified pharmaceutical products sold in India.

The current operative order is DPCO 2013, which replaced the earlier DPCO 1995. DPCO 2013 significantly expanded the list of price-controlled products compared to its predecessor.

---

The NLEM and Scheduled Formulations

DPCO 2013 determines controlled prices based on the National List of Essential Medicines (NLEM). Formulations containing molecules listed on the NLEM are classified as Scheduled Formulations — their ceiling prices are calculated and notified by NPPA.

The NLEM is periodically reviewed and updated by the Ministry of Health and Family Welfare. The current NLEM includes medicines across essential therapeutic categories, reflecting WHO's Essential Medicines concept applied to the Indian context.

NPPA publishes ceiling prices for Scheduled Formulations on its website (nppa.gov.in) — these are publicly available and searchable by drug name.

---

How Ceiling Prices Are Calculated

Under DPCO 2013, ceiling prices for Scheduled Formulations are based on a market-based pricing formula:

The ceiling price is calculated as the simple average of all branded versions of a formulation that have at least 1% market share in IQVIA's retail audit data (or equivalent), adjusted by a trade margin factor.

This market-based approach differs from the cost-based approach of DPCO 1995, and has been subject to ongoing policy discussion regarding its effectiveness in ensuring affordability.

For non-Scheduled Formulations (products not on the NLEM), the DPCO does not fix a ceiling price — but NPPA retains the authority to regulate prices of non-Scheduled drugs in cases of extraordinary price increases (under Paragraph 19 of DPCO 2013).

---

What DPCO Means for Export Buyers

For DPCO-controlled products, the domestic MRP (which cannot exceed the NPPA ceiling price) reflects a price set for the Indian domestic market. Your export purchase price is separately negotiated and will typically be lower than the domestic MRP — because the export pricing removes domestic distribution margins and is subject to competitive negotiation.

Do not use domestic MRP as a benchmark for your expected export purchase price. They are different pricing constructs.

The fact that a medicine is on the NLEM and DPCO-controlled tells you it is considered an essential medicine in India — it is typically produced by multiple manufacturers, widely available in the market, and has an established quality track record. This is generally positive context for export procurement.

For DPCO-controlled products, the NPPA ceiling price formula uses market share data — meaning products on the NLEM with notified prices have sufficient commercial presence to appear in retail audit data. This is a mild indication of established market presence, not a direct quality assurance.

---

Non-Scheduled Formulations: The Larger Market

It is worth noting that the majority of pharmaceutical formulations in the Indian market (by product count, though not necessarily by essential-medicine coverage) are non-Scheduled — not subject to DPCO ceiling prices. For these products, pricing is determined by market forces, though NPPA monitors for excessive increases.

For export buyers sourcing non-Scheduled formulations, commercial negotiation is the pricing mechanism — there is no regulatory floor or ceiling relevant to export transactions.

---

Practical Guidance for Buyers

- Use NPPA's public price list to understand domestic pricing context for NLEM molecules — but negotiate export pricing independently - DPCO applicability is not a direct quality indicator; apply your standard quality due diligence regardless of whether a product is DPCO-controlled - For current NLEM and NPPA price lists, refer to nppa.gov.in and Ministry of Health publications

---